Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559941 | 0.82 | NOTUM (0.31) | — | |
| SCHEMBL1425995 | 0.82 | NOTUM (0.31) | — | |
| SCHEMBL5513611 | 0.82 | ALDH1A1 (0.45) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL19876131 | 0.81 | ALDH1A1 (0.33) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL18935880 | 0.79 | NOTUM (0.40) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL14355599 | 0.77 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL30784392 | 0.77 | IMPDH2 (0.31) | ALDH1A1 | |
| SCHEMBL6561003 | 0.77 | CYP3A4 (0.40) | ALDH1A1 | |
| SCHEMBL24697150 | 0.77 | CYP3A4 (0.35) | ALDH1A1 | |
| SCHEMBL30040952 | 0.77 | CYP3A4 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118085884-A | Isothiocyanate liquid crystal compound containing 2, 3-difluoro-substituted benzene and liquid crystal composition | 西安近代化学研究所 | 2024-05-28 | — | — | CN | disclosed |
| WO-2021085279-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, SENSOR, LIQUID CRYSTAL LENS, OPTICAL COMMUNICATION DEVICE, AND ANTENNA | DIC株式会社 | 2021-05-06 | — | — | WO | disclosed |
| US-20170298081-A1 | CONDENSED HETEROCYCLIC COMPOUND | KASUMA PARTNERS INC. (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170298081-A1 | CONDENSED HETEROCYCLIC COMPOUND | KASUMA PARTNERS INC. (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170298081-A1 | CONDENSED HETEROCYCLIC COMPOUND | KASUMA PARTNERS INC. (JP) | 2017-10-19 | — | — | US | disclosed |
| EP-3178810-A1 | CONDENSED HETEROCYCLIC COMPOUND | Kasuma Partners Inc. (JP) | 2017-06-14 | — | — | EP | disclosed |
| EP-3178810-A1 | CONDENSED HETEROCYCLIC COMPOUND | Kasuma Partners Inc. (JP) | 2017-06-14 | — | — | EP | disclosed |
| EP-2091941-B1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-01-23 | — | — | EP | disclosed |
| US-8088783-B2 | MAPK/ERK kinase inhibitors | DONG QING (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110190261-A1 | MAPK/ERK Kinase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| US-7943626-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20100204471-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | US | disclosed |
| US-20100113413-A1 | MAPK/ERK Kinase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7696218-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA SAN DIEGO, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2091941-A2 | MAPK/ERK KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008140553-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190261-A1 | MAPK/ERK Kinase Inhibitors | MAPK1, MAPK4, MAPK6 | ALDH1A1 1803/4885CA12 4838/4885CA1 4492/4885 |
| US-20100204471-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | ALDH1A1 2921/4885CA12 4512/4885CA1 4533/4885 |
| US-20170298081-A1 | CONDENSED HETEROCYCLIC COMPOUND | APOB, NPC1, NPC1L1 | ALDH1A1 2120/4885CA12 2891/4885CA1 3316/4885 |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | ALDH1A1 2921/4885CA12 4512/4885CA1 4533/4885 |
| US-20100113413-A1 | MAPK/ERK Kinase Inhibitors | MAPK1, MAPK6, MAPK4 | ALDH1A1 1553/4885CA12 4808/4885CA1 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.